Haemophilus influenzae type b vaccination: Long-term protection

Jornal de Pediatria

Volumn 82, Issue SUPPL. 1, 2006, Pages

  Nascimento Carvalho, Cristiana M ^a,c   De Andrade, Ana Lúcia S Sgambatti ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c NONE   (Brazil)

Author keywords

Haemophilus influenzae type b; Immunization; Meningitis; Pneumonia; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

BACTERIAL INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INCIDENCE; MASS IMMUNIZATION; MENINGITIS; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; REVIEW; VACCINATION;

HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MENINGITIS, HAEMOPHILUS; POLYSACCHARIDES, BACTERIAL; TIME FACTORS; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE; WORLD HEALTH;

EID: 33750529938     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1501     Document Type: Review

References (64)

1. World Health Organization. Haemophilus influenzae type b Hib meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case fatality rates. Geneva: WHO, Department of Vaccines and Biologicals; 2002. (WHO/V&B/02.18.) http://www.who.int/vaccines-documents/DocsPDF02/www696.pdf. Access: 20/02/2006.
2. Aristegui J, Usonis V, Coovadia H, Riedemann S, Win KM, Gatchalian S, et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis. 2003;7:143-51.
3. Mallet E, Belohradsky BH, Lagos R, Gothefors L, Camier P, Carriere JP, et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine. 2004;22:1343-57.
4. Levine OS, Ortiz E, Contreras R, Lagos R, Vial P, Misraji A, et al. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile. Am J Epidemiol. 1993;137:1221-8.
5. Lagos R, Levine OS, Avendano A, Horwitz I, Levine MM. The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. Pediatr Infect Dis J. 1998;17(9 Suppl):S139-48.
6. Mahoney RT, Ramachandran S, Xu Z. The introduction of new vaccines into developing countries II. Vaccine financing. Vaccine. 2000;18:2625-35.
7. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? In: Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr. 2003;143(6 Suppl):S163-87.
8. Bijlmer HA. World-wide epidemiology of Haemophilus influenzae meningitis: industrialized versus non-industrialized countries. Vaccine. 1991;9 Suppl:S5-9.
9. World Health Organization. Estimating the local burden of Haemophilus influenzae type b Hib disease preventable by vaccination. Geneva: WHO; 2001. (WHO/V&B/01.27.) http://www.who.int/vaccines-documents/DocsPDF01/www.625. pdf. Access: 18/04/2006.
10. Di Fabio JL, de Quadros C. Considerations for combination vaccine development and use in the developing world. Clin Infect Dis. 2001;33 Suppl 4:S340-5.
11. World Health Organization. Countries using Hib vaccine in their national infant immunization system, as of December 2003. http://www.who.int/vaccines- surveillance/graphics/htmls/hibmap.htm. Access: 18/04/2006.
12. Levine OS, Schwartz B, Pierce N, Kane M. Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Pediatr Infect Dis J. 1998;17(9 Suppl):S95-113.
13. Feikin DR, Nelson CB, Watt JP, Mohsni E, Wenger JD, Levine OS. Rapid assessment tool for Haemophilus influenzae type b disease in developing countries. Emerg Infect Dis. 2004;10: 1270-6.
14. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302-17.
15. Peltola H. Spectrum and burden of severe Haemophilus influenzae type b diseases in Asia. Bull World Health Organ. 1999;77:878-87.
16. Gessner BD. Worldwide variation in Haemophilus influenzae type b meningitis incidence and its association with ampicillin resistance. Eur J Clin Microbiol Infect Dis. 2002;21:79-87.
17. Kim JS, Jang YT, Kim JD, Park TH, Park JM, Kilgore PE, et al. Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. Vaccine. 2004;22: 3952-62.
18. Saha SK, Baqui AH, Darmstadt GL, Ruhulamin M, Hanif M, El Arifeen S, et al. Invasive Haemophilus influenzae type B diseases in Bangladesh, with increased resistance to antibiotics. J Pediatr. 2005;146:227-33.
19. Gessner BD, Sutanto A, Linehan M, Djelantik IG, Fletcher T, Gerudug IK, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet. 2005;365:43-52.
20. Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J. 1996;15:216-22.
21. Weiss DP, Coplan P, Guess H. Epidemiology of bacterial meningitis among children in Brazil, 1997-1998. Rev Saude Publica. 2001;35:249-55.
22. Simoes LL, Andrade AL, Laval CA, Oliveira RM, Silva SA, Martelli CM, et al. Impact of Haemophilus influenzae b (Hib) vaccination on meningitis in Central Brazil. Rev Saude Publica. 2004;38:664-70.
23. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine corrected for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997;349:1191-7.
24. Levine OS, Lagos R, Munoz A, Villaroel J, Alvares AM, Abrego P, et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J. 1999;18:1060-4.
25. Mulholland EK. Use of vaccine trials to estimate burden of disease. J Health Popul Nutr. 2004;22:257-67.
26. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269:221-6.
27. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J. 1998;17(9 Suppl):S117-22.
28. Salisbury DM. The introduction of Haemophilus influenzae type b immunization into the United Kingdom: practical steps to assure success. Pediatr Infect Dis J. 1998;17(9 Suppl):S136-9.
29. Slack MP, Azzopardi HJ, Hargreaves RM, Ramsay ME. Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Pediatr Infect Dis J. 1998;17(9 Suppl):S204-7.
30. Dawson KG, Emerson JC, Burns JL. Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J. 1999;18:816-22.
31. Laval CA, Pimenta FC, de Andrade JG, Andrade SS, de Andrade AL. Progress towards meningitis prevention in the conjugate vaccines era. Braz J Infect Dis. 2003;7:315-24.
32. Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005;366:144-50.
33. Centers for Diseases Control and Prevention. Heamophilus influenzae type b. http://www.cdc.gov/nip/publications/pink/hib.pdf. Access: 20/02/2006.
34. Ruocco G, Curto S, Savio M, Laurani H, Frocht R. Vaccination against Haemophilus influenzae type b in Uruguay: experience and impact. Rev Panam Salud Publica. 1999;5:197-9.
35. Landaverde M, Di Fabio JL, Ruocco G, Leal I, de Quadros C. Introduction of a conjugate vaccine against Hib in Chile and Uruguay. Rev Panam Salud Publica. 1999;5:200-6.
36. Agudelo CI, Munoz N, De la Hoz F. Rapid assessment of the impact of Haemophilus influenzae vaccine serotype b in Colombia. Public Health Laboratories. Rev Panam Salud Publica. 2000;8: 181-4.
37. Freitas H. Meningite por Haemophilus influenzae b no Distrito Federal. Aspectos epidemiológicos e impacto após introdução da vacina [dissertação]. Brasília: Universidade de Brasília; 2000.
38. Takemura NS, Andrade SM. Meningite por Haemophilus influenzae tipo b em cidades do estado do Paraná, Brasil. J Pediatr (Rio J). 2001;77:387-92.
39. Dickinson FO, Perez AE, Galindo MA, Quintana I. Impact of vaccination against Haemophilus influenzae type b in Cuba. Rev Panam Salud Publica. 2001;10:169-73.
40. Diaz JM, Catalan L, Urrutia MT, Prado J, Valeria P, Lederman W, et al. Tendencias en la etiología de la meningitis bacteriana aguda en niños chilenos, período 1989-1998: impacto de la vacuna anti-H influenzae tipo b (Hib). Rev Med Chil. 2001;129:719-26.
41. Ribeiro GS, Reis JN, Cordeiro SM, Lima JB, Gouveia EL, Petersen M, et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis. 2003;187:109-16.
42. Kmetzsch CI, Schermann MT, Santana JC, Estima CL, Faraco FJ, Silva CM, et al. Occurrence of Haemophylus influenzae B meningitis after the implementation of a mass vaccination program. J Pediatr (Rio J). 2003;79:530-6.
43. de Andrade AL, de Andrade JG, Martelli CM, e Silva SA, de Oliveira RM, Costa MS, et al. Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol. 2004;33:173-81.
44. de la Hoz F, Higuera AB, Di Fabio JL, Luna M, Naranjo AG, de la Luz Valencia M, et al. Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine. 2004;23:36-42.
45. Review panel on Haemophilus influenzae type b (Hib) disease burden in Bangladesh, Indonesia and other Asian countries, Bangkok, 28-29 January 2004. Wkly Epidemiol Rec. 2004;79:173-5.
46. Nelson CM, Sutanto A, Gessner BD, Suradana IG, Steinhoff MC, Arjoso S. Age and cause- specific childhood mortality in Lombok, Indonesia, as a factor for determining the appropriateness of introducing Haemophilus influenzae type b and pneumococcal vaccines. J Health Popul Nutr. 2000;18:131-8.
47. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS; Bellagio Child Survival Study Group. How many child deaths can we prevent this year? Lancet. 2003;362:65-71.
48. Andrade ALSS, Afonso ET, Silva SA, Neto OLM, Marques SM, Martelli CMT. Invasive Disease-related mortality among children before and after the introduction of the Haemophilus influenzae type B conjugate vaccine in Brazil. Int J Infect Dis. 2004;8(Suppl 1):75.
49. Garner D, Weston V. Effectiveness of vaccination for Haemophilus influenzae type b. Lancet. 2003;361:395-6.
50. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health. 2003;6:55-8.
51. van Alphen L, Spanjaard L, van der Ende A, Schuurman I, Dankert J. Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. J Pediatr. 1997;131:869-73.
52. Rijkers GT, Vermeer-de Bondt PE, Spanjaard L, Breukels MA, Sanders EA. Return of Haemophilus influenzae type b infections. Lancet. 2003;361:1563-4.
53. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis. 2003;188:481-5.
54. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet. 2003;361:1523-4.
55. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 2003;361:1521-3.
56. Sarangi J, Cartwright K, Stuart J, Brookes S, Morris R, Slack M. Invasive Haemophilus influenzae disease in adults. Epidemiol Infect. 2000;124:441-7.
57. McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ. 2004;329:655-8.
58. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100.
59. Heath PT, Booy R, Azzopardi HJ, Slack MP, Bowen-Morris J, Griffiths H, et al. Antibody concentration and clinical protection after Hib conjugate vaccination the United Kingdom. JAMA. 2000;284:2334-40.
60. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis. 1995;171:93-8.
61. McVernon J, Mitchison NA, Moxon ER. T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect Dis. 2004;4:40-3.
62. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus- pertussis containing acellular pertussis. Lancet. 1999;354:2063-8.
63. Fitzgerald M, Canny M, O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill. 2005;10:E050929.3.
64. American Academy of Pediatrics. Recommended childhood and adolescent immunization schedule - United States, 2003. In: Pickering LK, editor. 2003 red book: report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village: American Academy of Pediatrics; 2003. p. 24.